Log in

Relevant bibliographies by topics / Benralizumab / Journal articles

To see the other types of publications on this topic, follow the link: Benralizumab.

Journal articles on the topic 'Benralizumab'

Author: Grafiati

Published: 14 March 2023

Last updated: 25 July 2025

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the top 50 journal articles for your research on the topic 'Benralizumab.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Browse journal articles on a wide variety of disciplines and organise your bibliography correctly.

1

Pini, Laura, Diego Bagnasco, Bianca Beghè, et al. "Unlocking the Long-Term Effectiveness of Benralizumab in Severe Eosinophilic Asthma: A Three-Year Real-Life Study." Journal of Clinical Medicine 13, no. 10 (2024): 3013. http://dx.doi.org/10.3390/jcm13103013.

Full text

Abstract:

Background: Benralizumab has been shown to restore good control of severe eosinophilic asthma (SEA). Robust data on benralizumab effectiveness over periods longer than 2 years are scarce. Methods: This retrospective multicentric study was conducted on 108 Italian SEA patients treated with benralizumab for up to 36 months. Partial and complete clinical remission (CR) were assessed. Data were analyzed with descriptive statistics or using linear, logistic, and negative binomial mixed-effect regression models. Results: At 36 months, benralizumab reduced the exacerbation rate by 89% and increased t

APA, Harvard, Vancouver, ISO, and other styles

2

Malakauskas, Kęstutis, Kristina Biekšienė, Marius Zolubas, et al. "Benralizumabo veiksmingumas gydant sunkia eozinofiline astma sergančius pacientus. BREEZE tyrimo Lietuvos duomenys." Pulmonology and allergology 8, no. 2 (2024): 175–80. http://dx.doi.org/10.37499/pia.1486.

Full text

Abstract:

Retrospektyvusis benralizumabo tyrimas BREEZE, skirtas apibūdinti pacientų savybes, gydymo būdus ir rezultatus klinikinėje praktikoje Vidurio Rytų Europos ir Baltijos šalyse, yra tarptautinės programos XALOC dalis. Daugiacentrių Lietuvos klinikinės praktikos tyrimų duomenų, gydant sergančiuosius sunkia eozinofiline astma benralizumabu, nėra. Tikslas. Įvertinti benralizumabo veiksmingumą klinikinėje praktikoje, gydant sunkia eozinofiline astma sergančius pacientus Lietuvoje. Tyrimo metodai. Šiame tyrime aprašomi Lietuvos pacientų, dalyvavusių BREEZE tyrime, duomenys. Į tyrimą įtraukti suaugę pa

APA, Harvard, Vancouver, ISO, and other styles

3

Miguel Reyes, José Luis, Erika del Carmen López Estrada, Monserrat Arroyo Rojas, et al. "Benralizumab in severe eosinophilic asthma: A real-world, single-center, observational study from Mexico." Allergologia et Immunopathologia 51, no. 6 (2023): 8–15. http://dx.doi.org/10.15586/aei.v51i6.852.

Full text

Abstract:

Introduction: Urbanization has increased the prevalence of asthma in lower- and middle-income countries. Severe eosinophilic asthma (SEA), a subtype of asthma, can be refractory to standard therapy. Biologics such as benralizumab target interleukin-5 and have demonstrated effectiveness in managing SEA. There exists no real-world evidence on the effectiveness of benralizumab in Mexico. Therefore, this study presents data on the role of benralizumab in managing SEA in Mexican patients. Objective: The effectiveness of benralizumab on the quality of life (QoL), asthma control, lung function, sympt

APA, Harvard, Vancouver, ISO, and other styles

4

Antoniu, S. A. "Benralizumab." Drugs of the Future 39, no. 7 (2014): 463. http://dx.doi.org/10.1358/dof.2014.039.07.2156125.

Full text

APA, Harvard, Vancouver, ISO, and other styles

5

Antoniu, S. A. "Benralizumab." Drugs of the Future 39, no. 7 (2014): 463. http://dx.doi.org/10.1358/dof.2014.39.7.2156125.

Full text

APA, Harvard, Vancouver, ISO, and other styles

6

Sandhu, Yuuki, Norihiro Harada, Hitoshi Sasano, et al. "Pretreatment Frequency of Circulating Th17 Cells and FeNO Levels Predicted the Real-World Response after 1 Year of Benralizumab Treatment in Patients with Severe Asthma." Biomolecules 13, no. 3 (2023): 538. http://dx.doi.org/10.3390/biom13030538.

Full text

Abstract:

Benralizumab treatment reduces exacerbations and improves symptom control and quality of life in patients with severe eosinophilic asthma. However, the determination of biomarkers that predict therapeutic effectiveness is required for precision medicine. Herein, we elucidated the dynamics of various parameters before and after treatment as well as patient characteristics predictive of clinical effectiveness after 1 year of benralizumab treatment in severe asthma in a real-world setting. Thirty-six patients with severe asthma were treated with benralizumab for 1 year. Lymphocyte subsets in peri

APA, Harvard, Vancouver, ISO, and other styles

7

Zhuravleva, M. V., S. N. Avdeev, Yu V. Gagarina, and T. V. Marin. "Pharmacoeconomic analysis of using benralizumab for treatment of severe asthma in inpatient and outpatient settings." FARMAKOEKONOMIKA. Modern Pharmacoeconomics and Pharmacoepidemiology 15, no. 2 (2022): 175–86. http://dx.doi.org/10.17749/2070-4909/farmakoekonomika.2022.143.

Full text

Abstract:

Objective: evaluation of the pharmacoeconomic feasibility of using benralizumab in the form of autoinjector (pen-injector device) in outpatient facilities compared with its use in the form of a syringe in hospital settings for the treatment of severe asthma (SA).Material and methods. The cost minimization and budget impact analysis methods were used. The current practice of treating patients with SA with benralizumab in hospital settings at the expense of compulsory medical insurance funds was compared with the simulated practice. The simulated price was calculated as half patients receiving b

APA, Harvard, Vancouver, ISO, and other styles

8

Shnaider, К. О., M. L. Maksimov, and S. А. Martynova. "Efficacy and safety of benralizumab." Glavvrač (Chief Medical Officer), no. 10 (October 12, 2024): 31–46. http://dx.doi.org/10.33920/med-03-2410-03.

Full text

Abstract:

The purpose of the review is to analyze Russian and foreign literature sources on the effectiveness and safety of benralizumab in the treatment of moderate and severe bronchial asthma. Benralizumab is a humanized monoclonal antibody directed against the interleukin-5 receptor (IL-5R) subunit. Binding of benralizumab with the alpha chain of IL-5R leads to inhibition of hetero-oligomerization of alpha and beta subunits, thus preventing signal transduction and consequent proliferation of eosinophils and basophils and the cascade of events following it. Benralizumab significantly reduces annual as

APA, Harvard, Vancouver, ISO, and other styles

9

Bourdin, Arnaud, Don Husereau, Nicolas Molinari, et al. "Matching-adjusted indirect comparison of benralizumab versus interleukin-5 inhibitors for the treatment of severe asthma: a systematic review." European Respiratory Journal 52, no. 5 (2018): 1801393. http://dx.doi.org/10.1183/13993003.01393-2018.

Full text

Abstract:

Benralizumab is an interleukin-5 receptor α-directed cytolytic monoclonal antibody that directly depletes eosinophils. Its relative efficacy versus other IL-5-targeted treatments for patients with severe, uncontrolled asthma is not yet fully characterised.We performed a matching-adjusted indirect comparison (MAIC) of benralizumab versus mepolizumab and reslizumab. Trials were selected through systematic review and evaluation of trial methods. Benralizumab patient-level data were weighted to match treatment-effect-modifying patient characteristics of comparator trials before indirect efficacy c

APA, Harvard, Vancouver, ISO, and other styles

10

Menzella, Francesco, Mariarita Marchi, Marco Caminati, et al. "Long-Term Eosinophil Depletion: A Real-World Perspective on the Safety and Durability of Benralizumab Treatment in Severe Eosinophilic Asthma." Journal of Clinical Medicine 14, no. 1 (2024): 191. https://doi.org/10.3390/jcm14010191.

Full text

Abstract:

Background/Objectives: Benralizumab is an anti-IL-5 receptor alpha monoclonal antibody that induces the near-complete depletion of eosinophils. This study aimed to evaluate the long-term safety and effectiveness of benralizumab in patients with severe eosinophilic asthma (SEA) over an extended 48-month follow-up period, offering one of the longest real-world perspectives available. Methods: This was a single-arm, retrospective, observational, multicenter study involving 123 SEA patients treated with benralizumab at a dosage of 30 mg every 4 weeks for the first 3 doses and then every 8 weeks. T

APA, Harvard, Vancouver, ISO, and other styles

11

Scioscia, Giulia, Pasquale Tondo, Santi Nolasco, et al. "Benralizumab in Patients with Severe Eosinophilic Asthma: A Multicentre Real-Life Experience." Journal of Clinical Medicine 12, no. 13 (2023): 4362. http://dx.doi.org/10.3390/jcm12134362.

Full text

Abstract:

Background: Mepolizumab and benralizumab are monoclonal antibodies directed against anti-IL-5 and anti-IL5R, respectively, and their use reduces the exacerbation rate and maintains oral corticosteroid requirements in severe eosinophilic asthma. Previous studies have tested the therapeutic switch between two biologics with excellent results, further demonstrating the heterogeneity of asthmatic disease and the complexity of the therapeutic choice. It remains unclear if such patients may improve following a switch from mepolizumab to benralizumab. Aims: Within a multicentre real-life setting, we

APA, Harvard, Vancouver, ISO, and other styles

12

Naumova, V. V., E. К. Beltyukov, K. A. Zykov та ін. "Effectiveness of anti-IL-5Rα-therapy in patients with T2-inflammatory airway diseases in real clinical practice". Meditsinskiy sovet = Medical Council, № 20 (11 грудня 2024): 40–50. https://doi.org/10.21518/ms2024-499.

Full text

Abstract:

Introduction. There is insufficient data on effectiveness and safety of targeted drugs aimed at T2 inflammation in real-life practice.Aim. To evaluate benralizumab effectiveness in patients with T2-inflammatory airway diseases in real-life clinical practice and to identify predictors of a positive response to therapy.Materials and methods. Patients' data from Sverdlovsk region registry with non-allergic eosinophilic (n = 32) and mixed (n = 6) severe asthma received benralizumab were analyzed. Reduction in proportion of patients requiring systemic GCS and proportion of patients with a good resp

APA, Harvard, Vancouver, ISO, and other styles

13

Sakai, Natsumi, Toshiyuki Koya, Yui Murai, et al. "Effect of Benralizumab on Mucus Plugs in Severe Eosinophilic Asthma." International Archives of Allergy and Immunology 184, no. 8 (2023): 783–91. http://dx.doi.org/10.1159/000530392.

Full text

Abstract:

<b><i>Introduction:</i></b> Mucus plugs are associated with airway obstruction in severe asthma and are involved in the formation of activated eosinophils. Benralizumab, an anti-interleukin-5 receptor antibody, markedly reduces not only peripheral blood eosinophils but also airway eosinophils; however, its effects on mucus plugs have not been clarified. In this study, we examined the efficacy of benralizumab on mucus plugs using computed tomography (CT) imaging. <b><i>Methods:</i></b> Twelve patients who were administered benralizumab and underwe

APA, Harvard, Vancouver, ISO, and other styles

14

Ando, Koichi, Akihiko Tanaka, and Hironori Sagara. "Comparative Efficacy and Safety of Dupilumab and Benralizumab in Patients with Inadequately Controlled Asthma: A Systematic Review." International Journal of Molecular Sciences 21, no. 3 (2020): 889. http://dx.doi.org/10.3390/ijms21030889.

Full text

Abstract:

No head-to-head trials have compared the efficacy and safety between the licensed dosage and administration dosage of dupilumab and benralizumab for inadequately controlled asthma. We conducted an indirect treatment comparison to estimate differences in the efficacy and safety between dupilumab and benralizumab for inadequately controlled asthma using the Bayesian approach. The primary efficacy endpoint was annual exacerbation rate (AER). A subgroup analysis by blood eosinophil count was also performed. The primary safety endpoint was the incidence of any adverse events (AAEs). The results dem

APA, Harvard, Vancouver, ISO, and other styles

15

Bleecker, Eugene R., Michael E. Wechsler, J. Mark FitzGerald, et al. "Baseline patient factors impact on the clinical efficacy of benralizumab for severe asthma." European Respiratory Journal 52, no. 4 (2018): 1800936. http://dx.doi.org/10.1183/13993003.00936-2018.

Full text

Abstract:

Benralizumab is an anti-eosinophilic monoclonal antibody that reduces exacerbations and improves lung function for patients with severe, uncontrolled asthma with eosinophilic inflammation. We evaluated the impact of baseline factors on benralizumab efficacy for patients with severe asthma.This analysis used pooled data from the SIROCCO (ClinicalTrials.gov identifier NCT01928771) and CALIMA (ClinicalTrials.gov identifier NCT01914757) Phase III studies. Patients aged 12–75 years with severe, uncontrolled asthma receiving high-dosage inhaled corticosteroids plus long-acting β2-agonists received b

APA, Harvard, Vancouver, ISO, and other styles

16

Almulhim, Rayanah Nouraldeen, Abdullah Hamad Alsabhawi, Amnah Ali Alkhawajah, et al. "Efficacy of Benralizumab in Paediatric and Adult Populations with Chronic Rhinosinusitis with Nasal Polyps: A Systematic Review and Meta-analysis." Journal of Advanced Trends in Medical Research 1, no. 2 (2024): 409–15. https://doi.org/10.4103/atmr.atmr_155_24.

Full text

Abstract:

Abstract Background: Chronic rhinosinusitis with nasal polyps (CRSwNP) is a chronic inflammatory condition of the nasal and sinus mucosa, characterised by the symptoms such as nasal congestion, facial pain and a diminished sense of smell. Despite available treatments, including intranasal corticosteroids and surgery, many patients experience persistent symptoms and a reduced quality of life. Benralizumab, a monoclonal antibody targeting the interleukin-5 receptor alpha, has emerged as a potential therapeutic option for CRSwNP due to its ability to target eosinophils, a key cell type involved i

APA, Harvard, Vancouver, ISO, and other styles

17

Yamada, Hideyasu, Masayuki Nakajima, Masashi Matsuyama, et al. "Identification of distinct phenotypes related to benralizumab responsiveness in patients with severe eosinophilic asthma." PLOS ONE 16, no. 3 (2021): e0248305. http://dx.doi.org/10.1371/journal.pone.0248305.

Full text

Abstract:

Purpose To characterize the clinical phenotypes of severe eosinophilic asthma based on early responsiveness to benralizumab in terms of forced expiratory volume in 1 second (FEV1) improvement. Patients and methods Sixty-four participants diagnosed with severe eosinophilic asthma and who had completed 4 months of benralizumab treatment were included in this analysis. Pre-treatment clinical factors were compared between responders and non-responders according to improvements in ACT or FEV1. Correlations between the sums of increased Type 2-related inflammatory parameters and changes of ACT or FE

APA, Harvard, Vancouver, ISO, and other styles

18

Titova, Olga N., Natalia A. Kuzubova, Daria B. Sklyarova, and Maria A. Petrova. "The effectiveness of benralizumab in the treatment of the eosinophilic phenotype of severe asthma in real clinical practice." PULMONOLOGIYA 31, no. 5 (2021): 628–34. http://dx.doi.org/10.18093/0869-0189-2021-31-5-628-634.

Full text

Abstract:

To evaluate the effectiveness of benralizumab in patients with the eosinophilic phenotype of severe asthma in real clinical practice after a year of therapy.Methods. During Benralizumab therapy, 13 patients with severe eosinophilic asthma (average age – 55.44 ± 7.18 years old) were examined twice: before the treatment and after 1 year of benralizumab therapy. The assessment included collection of complaints, medical history, current therapy, Asthma Control Questionnaire (ACQ-5) test, absolute blood count of eosinophils, spirometry.Results. All patients initially had pronounced eosinophilia of

APA, Harvard, Vancouver, ISO, and other styles

19

Fomina, D. S., G. L. Ignatova, T. G. Kabanova, et al. "Efficacy of benralizumab in severe eosinophilic asthma: an interim analysis of a real clinical practice prospective study BEST in Russia." PULMONOLOGIYA 33, no. 3 (2023): 374–85. http://dx.doi.org/10.18093/0869-0189-2023-33-3-374-385.

Full text

Abstract:

Systematizing clinical experience in the use of biological treatments in patients with severe bronchial asthma in real world settings with assessment of clinical outcomes and quality of life level is of great interest and value in practical pulmonology.The aim of the BEST study (Real World Evidence of Benralizumab in Eosinophilic Severe AsThma in Russia) was to evaluate effectiveness of benralizumab by control and quality of life associated with respiratory status in patients with eosinophilic phenotype of severe asthma in real clinical practice in Russia.Results. The results obtained through

APA, Harvard, Vancouver, ISO, and other styles

20

Tsurumaki, Matsuyama, Ezawa, et al. "Rapid Effect of Benralizumab for Hypereosinophilia in a Case of Severe Asthma with Eosinophilic Chronic Rhinosinusitis." Medicina 55, no. 7 (2019): 336. http://dx.doi.org/10.3390/medicina55070336.

Full text

Abstract:

A 56-year-old man with severe asthma underwent bronchial thermoplasty (BT). However, his asthma exacerbated and hypereosinophilia developed 2 months later, thus necessitating oral corticosteroid (OCS) therapy. Six months after BT, a diagnosis of severe asthma with eosinophilic chronic rhinosinusitis (ECRS) was made and benralizumab treatment was initiated; the blood eosinophil count subsequently decreased and lung function improved, thereby permitting OCS dose tapering. Surprisingly, benralizumab both reduced nasal polyps and ameliorated ECRS. Thus, benralizumab may be a useful drug for the ra

APA, Harvard, Vancouver, ISO, and other styles

21

Nedogoda, Sergey Vladimirovich, Alla Sergeevna Salasyuk, Irina Nikolaevna Barykina, Victoria Olegovna Smirnova та Maksim Yurevich Frolov. "Сost of the Biologacal Therapy for Severe Brochcial Asthma Treatment at Inpatient and Day Care Setting". Medical Technologies. Assessment and Choice (Медицинские технологии. Оценка и выбор), № 1 (39) (1 травня 2020): 61–69. http://dx.doi.org/10.31556/2219-0678.2020.39.1.061-069.

Full text

Abstract:

Objective: to assess the cost of the severe bronchial asthma (BA) treatment with various biological agents at inpatient and day care setting from the compulsory medical insurance (CMI) system perspective. Methods. The authors constructed the MS Excel® analytical decision-making model and calculated the CMI system’s costs of severe BA treatment with various biological drugs at inpatient and day care setting. The costs of treatment with benralizumab, dupilumab, omalizumab, reslizumab and mepolizumab were compared. The cost difference between benralizumab and other drugs was identified taking int

APA, Harvard, Vancouver, ISO, and other styles

22

Chan, Rory, and Brian J. Lipworth. "Real-life effects of benralizumab on airway oscillometry in severe eosinophilic asthma." BMJ Open Respiratory Research 10, no. 1 (2023): e001472. http://dx.doi.org/10.1136/bmjresp-2022-001472.

Full text

Abstract:

IntroductionEosinophil depletion with benralizumab reduces exacerbations and improves disease control and FEV1in patients with severe eosinophilic asthma. However, few studies have investigated the effect of biologics on small airways dysfunction (SAD) even though the latter correlates better with poor asthma control and type 2 inflammation.Methods21 GINA-defined severe asthma patients who were treated with benralizumab and who had baseline oscillometry-defined SAD were included in this study. Here, SAD was diagnosed only if patients satisfied both R5–R20≥0.10 kPa/L/s and AX≥1.0 kPa/L. The mea

APA, Harvard, Vancouver, ISO, and other styles

23

Talwar, Deepak, Manoj Yadav, Nagarjuna Maturu, Rahul Sharma, Priti Meshram, and Soumya Das. "An early Indian experience with benralizumab - A compendium on severe asthma cases: a case series." F1000Research 12 (September 27, 2023): 1225. http://dx.doi.org/10.12688/f1000research.132704.1.

Full text

Abstract:

Background: Severe eosinophilic asthma (SEA), one of the phenotypes of asthma that is characterized by elevated blood eosinophil counts, is a common cause of uncontrolled asthma. Patients with SEA often experience severe persistent symptoms and have frequent exacerbations despite optimal inhaler therapy. They also have poor lung function and quality of life (QoL). Benralizumab (Fasenra), a monoclonal antibody, has been approved for managing cases of SEA. This series of six cases, the first of its kind from India, aims to add to the real-world evidence of benralizumab in India. Methods: Benrali

APA, Harvard, Vancouver, ISO, and other styles

24

Dr., M. Govardhan* Shaik Rizwana Alefiya Kotawala. "A Comprehensive Review on Drug Profile of Benralizumab." International Journal of Pharmaceutical Sciences 3, no. 3 (2025): 783–88. https://doi.org/10.5281/zenodo.15000067.

Full text

Abstract:

This comprehensive review explain that the drug profile of benralizumab, a monoclonal antibody approved by the FDA for the management of severe eosinophilic asthma and other eosinophilic conditions. Highlighting asthma as a chronic inflammatory disorder characterized by eosinophilic excess, the review classifies treatment options including corticosteroids, leukotriene modifiers, biologics, and bronchodilators. Specifically focusing on benralizumab, the review details its mechanism of action as an IL-5 receptor antagonist, leading to eosinophil depletion via apoptosis and antibody-dependent cel

APA, Harvard, Vancouver, ISO, and other styles

25

Ахмедханов, Seypula Sh, Saida G. Gadzhiyeva, Albina T. Beybalayeva, and Zaira M. Saidova. "Clinical case of benralizumab use in severe eosinophilic bronchial asthma in the Republic of Dagestan." Russian Family Doctor 27, no. 4 (2024): 51–58. http://dx.doi.org/10.17816/rfd569352.

Full text

Abstract:

This article presents the results of the examination, observation, and treatment of a patient with severe persistent bronchial asthma with an eosinophilic phenotype who received benralizumab (Fazenra) in a complex treatment. Benralizumab is indicated for patients with severe bronchial asthma with an eosinophilic phenotype in adult patients as an additional maintenance therapy, in which the use of glucocorticosteroids does not achieve control over the symptoms of the disease. With complex therapy, the inclusion of benralizumab led to positive dynamics of both clinical symptoms and indicators of

APA, Harvard, Vancouver, ISO, and other styles

26

Dagher, Rania, Varsha Kumar, Alan M. Copenhaver, et al. "Novel mechanisms of action contributing to Benralizumab's potent anti-eosinophilic activity." European Respiratory Journal, July 21, 2021, 2004306. http://dx.doi.org/10.1183/13993003.04306-2020.

Full text

Abstract:

Benralizumab is a humanised, anti-IL-5Rα monoclonal antibody with anti-eosinophilic activity. Lack of fucose (afucosylation) increases its affinity to CD16a and significantly enhances antibody-dependent cell-mediated cytotoxicity (ADCC) by NK cells. Although benralizumab proved clinically efficacious in clinical trials for patients with severe asthma and hypereosinophilic syndrome, in-depth characterisation of its anti-eosinophilic mechanisms of action remain elusive. Here, we further investigated the mechanisms involved in benralizumab's anti-eosinophilic activities. In the presence of NK cel

APA, Harvard, Vancouver, ISO, and other styles

27

"Benralizumab." Reactions Weekly 1914, no. 1 (2022): 126. http://dx.doi.org/10.1007/s40278-022-18712-0.

Full text

APA, Harvard, Vancouver, ISO, and other styles

28

"Benralizumab." Reactions Weekly 1895, no. 1 (2022): 95. http://dx.doi.org/10.1007/s40278-022-10520-1.

Full text

APA, Harvard, Vancouver, ISO, and other styles

29

"Benralizumab." Reactions Weekly 1898, no. 1 (2022): 115. http://dx.doi.org/10.1007/s40278-022-11708-9.

Full text

APA, Harvard, Vancouver, ISO, and other styles

30

"Benralizumab." Reactions Weekly 1883, no. 1 (2021): 82. http://dx.doi.org/10.1007/s40278-021-06037-1.

Full text

APA, Harvard, Vancouver, ISO, and other styles

31

"Benralizumab." Reactions Weekly 1891, no. 1 (2022): 72. http://dx.doi.org/10.1007/s40278-022-09324-8.

Full text

APA, Harvard, Vancouver, ISO, and other styles

32

"Benralizumab." Reactions Weekly 1926, no. 1 (2022): 130. http://dx.doi.org/10.1007/s40278-022-24408-2.

Full text

APA, Harvard, Vancouver, ISO, and other styles

33

"Benralizumab." Reactions Weekly 2034, no. 1 (2024): 72. http://dx.doi.org/10.1007/s40278-024-70445-6.

Full text

APA, Harvard, Vancouver, ISO, and other styles

34

"Benralizumab." Reactions Weekly 2037, no. 1 (2024): 87. https://doi.org/10.1007/s40278-024-71780-6.

Full text

APA, Harvard, Vancouver, ISO, and other styles

35

"Benralizumab." Reactions Weekly 2024, no. 1 (2024): 88. http://dx.doi.org/10.1007/s40278-024-66070-x.

Full text

APA, Harvard, Vancouver, ISO, and other styles

36

"Benralizumab." Reactions Weekly 2024, no. 1 (2024): 87. http://dx.doi.org/10.1007/s40278-024-66069-y.

Full text

APA, Harvard, Vancouver, ISO, and other styles

37

"Benralizumab." Reactions Weekly 2033, no. 1 (2024): 58. http://dx.doi.org/10.1007/s40278-024-70168-x.

Full text

APA, Harvard, Vancouver, ISO, and other styles

38

"Benralizumab." Reactions Weekly 2014, no. 1 (2024): 121. http://dx.doi.org/10.1007/s40278-024-61549-5.

Full text

APA, Harvard, Vancouver, ISO, and other styles

39

"Benralizumab." Reactions Weekly 2014, no. 1 (2024): 120. http://dx.doi.org/10.1007/s40278-024-61548-5.

Full text

APA, Harvard, Vancouver, ISO, and other styles

40

"Benralizumab." Reactions Weekly 2014, no. 1 (2024): 122. http://dx.doi.org/10.1007/s40278-024-61550-4.

Full text

APA, Harvard, Vancouver, ISO, and other styles

41

"Benralizumab." Reactions Weekly 1829, no. 1 (2020): 100. http://dx.doi.org/10.1007/s40278-020-85690-y.

Full text

APA, Harvard, Vancouver, ISO, and other styles

42

"Benralizumab." Reactions Weekly 1829, no. 1 (2020): 101. http://dx.doi.org/10.1007/s40278-020-85691-y.

Full text

APA, Harvard, Vancouver, ISO, and other styles

43

"Benralizumab." Reactions Weekly 1831, no. 1 (2020): 81. http://dx.doi.org/10.1007/s40278-020-86337-7.

Full text

APA, Harvard, Vancouver, ISO, and other styles

44

"Benralizumab." Reactions Weekly 1835, no. 1 (2020): 69. http://dx.doi.org/10.1007/s40278-020-87513-2.

Full text

APA, Harvard, Vancouver, ISO, and other styles

45

"Benralizumab." Reactions Weekly 1818, no. 1 (2020): 57. http://dx.doi.org/10.1007/s40278-020-82337-6.

Full text

APA, Harvard, Vancouver, ISO, and other styles

46

"Benralizumab." Reactions Weekly 1933, no. 1 (2022): 116. http://dx.doi.org/10.1007/s40278-022-28067-5.

Full text

APA, Harvard, Vancouver, ISO, and other styles

47

"Benralizumab." Reactions Weekly 1747, no. 1 (2019): 62. http://dx.doi.org/10.1007/s40278-019-59703-5.

Full text

APA, Harvard, Vancouver, ISO, and other styles

48

"Benralizumab." Reactions Weekly 1957, no. 1 (2023): 92. http://dx.doi.org/10.1007/s40278-023-39217-7.

Full text

APA, Harvard, Vancouver, ISO, and other styles

49

"Benralizumab." Reactions Weekly 1955, no. 1 (2023): 101. http://dx.doi.org/10.1007/s40278-023-38348-5.

Full text

APA, Harvard, Vancouver, ISO, and other styles

50

"Benralizumab." Reactions Weekly 2042, no. 1 (2025): 80. https://doi.org/10.1007/s40278-025-74879-4.

Full text

APA, Harvard, Vancouver, ISO, and other styles

We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!